At #AACR26: Results from CAR-PRISM Trial.
@OmarNadeemMD
says in a small trial for pts with high-risk smoldering myeloma, "This is the 1st time we've seen universal minimal residual disease negativity with a one-time treatment administration."
@DanaFarber

https://
bit.ly/4tmxcmW